Response to "Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases"

Adv Ther. 2020 Apr;37(4):1697-1700. doi: 10.1007/s12325-020-01274-5. Epub 2020 Mar 15.

¹ U.S. Medical Affairs, Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA.
² Division of Gastroenterology and Hepatology Department of Medicine, Mayo Clinic, Rochester, MN, USA. Kane.Sunanda@mayo.edu.

No abstract available

Keywords: IBD; Inflammatory bowel disease; Intravenous biologics; Oral small-molecule therapies.

Publication types